FDA Brief

Warning letters Drugs

FDA warning letter to

CAMA Wellness Center/IodoRios Company, LLC

LowIssued Mar 5, 2021Posted Mar 8, 2021Center for Drug Evaluation and Research

FDA warned CAMA Wellness Center/IodoRios that its IoWipe hand wipe was an unapproved, misbranded drug with COVID-19 prevention claims.

What happened

FDA reviewed www.cp.camacenter.com on February 8, 2021, and FTC reviewed the site on March 2, 2021; a related Facebook page directed consumers to the site. FDA found the website offered an iodine-based reusable hand wipe, IoWipe, with claims that it could prevent, treat, or destroy COVID-19. The letter cites package-insert and website/social-media statements as evidence the product was intended as an unapproved new drug and was misbranded.

What FDA found

  1. The hand wipe is an unapproved new drug because the company intended it to prevent or treat COVID-19 without FDA approval.

    section 505(a) of the FD&C Act, 21 U.S.C. § 355(a)
  2. The product is misbranded because its labeling and website claims misleadingly present it as safe or effective for COVID-19.

    section 502 of the FD&C Act, 21 U.S.C. § 352
  3. The company is prohibited from introducing or delivering the product into interstate commerce.

    sections 301(a) and (d) of the FD&C Act, 21 U.S.C. § 331(a) and (d)
  4. The company advertised that the product can prevent, treat, or cure disease without competent and reliable scientific evidence, including for COVID-19.

    FTC Act, 15 U.S.C. 41 et seq.

What FDA wants

FDA tells the company to immediately stop selling unapproved and unauthorized COVID-19 products and, within 48 hours, email COVID-19-Task-Force-CDER@fda.hhs.gov with the steps taken, how it will prevent recurrence, and supporting documents. FTC separately asks for an email within 48 hours to Richard Cleland describing actions taken.

Who should pay attention

  • retailers and online marketplaces selling hand wipes
  • companies making COVID-19 prevention claims
  • brands using websites and social media for sanitizer claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Medolife Rx D/B/A MedoLife Corp., AELIA, Inc. and Quanta Inc.

    FDA says Medolife sold unapproved Escozine drugs online with claims to treat cancer, HIV, and COVID-19.

    High risk
  2. www.ivermectin4covid.com

    FDA warned website ivermectin4covid.com for selling unapproved, misbranded ivermectin drugs claiming COVID-19 use.

    High risk
  3. Medical Mikes, Inc.

    FDA and FTC warned Medical Mikes over unapproved CBD claims to prevent or treat COVID-19.

    High risk
  4. Purecraft LLC

    FDA and FTC warn Purecraft LLC over CBD products marketed with unapproved COVID-19 prevention and treatment claims.

    High risk